ACAD · Acadia Pharmaceuticals Inc

- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year growth, respectively - Fourth quarter 2025 non-GAAP adjusted total revenues of $298 million and full year 2025 non-GAAP adjusted total revenues of $1.08 billion, reflecting 16% and 14% year-over-year growth, respectively - Fourth quarter 2025 NUPLAZID® GAAP net sales of $174 million, including a non-recurring IRA rebate accrual change in estimate; Fourth quarter non-GAAP NUPLAZID net sales of $189 million - Fourth quarter 2025 DAYBUE ® GAAP net sales of $110 million, reflecting 13% year-over-year growth - Full year 2026 guidance for total revenues of $1.22 to $1.28 billion, including NUPLAZID net sales of $760 to $790 million and DAYBUE net sales of $460 to $490 million Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. “Acadia closed 2025 with

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company’s website, acadia.com , under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust

Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until May 24, 2026. The conference call may also be accessed by registering for the call here . Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our

- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion by the CHMP upon its formal adoption. “While the negative trend vote is disappointing and not what we hoped for, we believe the strong data that supported the approval of trofinetide for the treatment of Rett syndrome in the United States, Canada, and Israel speak to the meaningful benefits that trofinetide can deliver,” said Catherine Owen Adams, Chief Executive Officer.

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis anticipated between August and October 2026 - U.S. launch of DAYBUE ® STIX on a limited basis begins Q1 2026, with full launch planned Q2 2026 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement,” said Catherine Owen Adams, Chief Executive Officer. “With approximately $1.7 billion in global projected net sales by 2028, our commercial engine